Photoclinic: Vaccine-Induced Herpes Zoster

A newly-published study identified specific groups of higher-risk children that could benefit most from monoclonal antibodies.

The news is full of stories about monkeypox, the recent changes to COVID-19 guidance, and the return of polio cases. What do clinicians need to know?

The American Academy of Pediatrics will continue to hold its own childhood vaccine schedule, as it has since the 1930s.

Contemporary Pediatrics sat down with Dr. Donna Hallas to discuss how to communicate with parents as well as how to address vaccines missed because of the pandemic.

Currently, Vimkunya is FDA-approved for use among individuals aged 12 years and older.

Six-month results from the phase 2 VLA1553-221 trial aligned with initial data and demonstrated immune response at day 180 among patients aged 1 to 11 years.